Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.281
Neutral
RSI(14)
48.523
Neutral
STOCH(KDJ)(9,3,3)
63.495
Sell
ATR(14)
1.099
High Vlolatility
CCI(14)
15.980
Neutral
Williams %R
51.506
Neutral
TRIX(12,20)
0.097
Sell
StochRSI(14)
0.000
Sell
Search
BIOAGE Labs Inc
BIOAAdd to Watchlist
17.660USD
-1.055-5.64%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
785.04MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of BIOAGE Labs Inc
Currency: USD Updated: 2026-05-15Key Insights
BIOAGE Labs Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 73 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 44.50.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BIOAGE Labs Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
BIOAGE Labs Inc Highlights
StrengthsRisks
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
Growing
The company is in a growing phase, with the latest annual income totaling USD 8.99M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 8.99M.
Undervalued
The company’s latest PE is -7.34, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 28.69M shares, decreasing 9.72% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 2.63K shares of this stock.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
43.857
Target Price
+134.34%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of BIOAGE Labs Inc is 7.07, ranking 128 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 2.77M, representing a year-over-year increase of 91.04%, while its net profit experienced a year-over-year increase of 72.13%.
Score
Financials
9.90
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.50
Operational Efficiency
2.91
Growth Potential
7.83
Shareholder Returns
7.19
BIOAGE Labs Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of BIOAGE Labs Inc is 7.51, ranking 103 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -7.34, which is -111.36% below the recent high of 0.83 and -57.30% above the recent low of -11.54.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 73/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of BIOAGE Labs Inc is 8.29, ranking 137 out of 382 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 15.00 and a low of 9.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
43.857
Target Price
+134.34%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
BIOAGE Labs Inc
BIOA
8
CRISPR Therapeutics AG
CRSP
27
Beigene Ltd
ONC
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of BIOAGE Labs Inc is 7.29, ranking 79 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 20.00 and the support level at 15.69, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
18.373
Sell
MA10
17.944
Sell
MA20
17.825
Sell
MA50
18.062
Sell
MA100
18.342
Sell
MA200
12.553
Buy
Institutional Confidence
Currency: USD Updated: 2026-05-15Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of BIOAGE Labs Inc is 3.28, ranking 147 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
+30.93%
240-Day Volatility
+78.51%
Return
Best Daily Return
60 days
+15.12%
120 days
+27.23%
5 years
--
Worst Daily Return
60 days
-13.53%
120 days
-13.53%
5 years
--
Sharpe Ratio
60 days
-0.15
120 days
+2.16
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+30.93%
3 years
--
5 years
--
Return-to-Drawdown Ratio
240 days
+10.86
3 years
--
5 years
--
Skewness
240 days
+1.97
3 years
--
5 years
--
Volatility
Realised Volatility
240 days
+78.51%
5 years
--
Standardised True Range
240 days
+4.60%
5 years
--
Downside Risk-Adjusted Return
120 days
+462.60%
240 days
+462.60%
Maximum Daily Upside Volatility
60 days
+62.27%
Maximum Daily Downside Volatility
60 days
+54.15%
Liquidity
Average Turnover Rate
60 days
+1.33%
120 days
+1.61%
5 years
--
Turnover Deviation
20 days
--
60 days
--
120 days
--
Peer Comparison
Biotechnology & Medical Research
BIOAGE Labs Inc
BIOA
6.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
